EICHORCondition: Triple Negative Breast Cancer Metastatic · Sponsor: IFOM ETS - The AIRC Institute of Molecular Oncology
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This study will evaluate the efficacy and safety of ceralasertib followed by durvalumab plus nab-paclitaxel in 37 patients with TNBC, whose tumor relapsed following treatment with curative intent for early disease, which must have included immunotherapy and chemotherapy as part of the radical locoregional therapy (either adjuvant, neoadjuvant or both).
This description comes directly from the study's public registry record.
Ylenia Silvestri, PhD · +3902574303797 · clinical.trials@ifom.eu
Smeralda Rapisarda, PhD · +3902574303236 · clinical.trials@ifom.eu
Always discuss trial participation with your own doctor first.
| Azienda Ospedaliero Universitaria Maggiore della Carità | Novara, Novara, Italy | Recruiting |
| ASST Papa Giovanni XXIII | Bergamo, Italy | Recruiting |
| Istituto Nazionale dei Tumori IRCCS | Milan, Italy | Recruiting |
| IRCCS Istituto Nazionale Tumori "Fondazione Giovanni Pascale" | Naples, Italy | Recruiting |
| Istituto Oncologico Veneto IRCCS | Padova, Italy | Recruiting |
| Azienda U.S.L. - IRCCS di Reggio Emilia | Reggio Emilia, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05582538